Phase II Study of MEDI4736 Monotherapy or in Combinations With Tremelimumab in Metastatic Pancreatic Ductal Carcinoma

Completed · Phase 2

Conditions studied: Metastatic Pancreatic Ductal Adenocarcinoma

In brief

A Phase II Open-Label, Multi-Center Study of MEDI4736 Evaluated as Single Agent or in Combination with Tremelimumab in Patients with Metastatic Pancreatic Ductal Adenocarcinoma.

Key facts

Study ID

NCT02558894

Run by

AstraZeneca

People needed

65

Starts

2015-11-16

Expected to finish

2017-06-15

Last updated by the study team

2018-08-02

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may not qualify if…

• Any concurrent chemotherapy, investigational product , biologic, or hormonal therapy for cancer treatment.
• History of leptomeningeal carcinomatosis
• Ascites requiring intervention
• Brain metastases or spinal cord compression.

Where it is running

• Research Site — Tampa, Florida, United States
• Research Site — New York, New York, United States
• Research Site — Vancouver, British Columbia, Canada
• Research Site — Oshawa, Ontario, Canada
• Research Site — Ottawa, Ontario, Canada
• Research Site — Toronto, Ontario, Canada
• Research Site — Toronto, Ontario, Canada
• Research Site — Montreal, Quebec, Canada
• Research Site — Friedrichshafen, Germany
• Research Site — München, Germany
• Research Site — Tübingen, Germany
• Research Site — Amsterdam, Netherlands
• Research Site — Groningen, Netherlands
• Research Site — Nijmegen, Netherlands
• Research Site — Seongnam-si, South Korea
• Research Site — Seoul, South Korea
• Research Site — Seoul, South Korea
• Research Site — Seoul, South Korea
• Research Site — Seoul, South Korea
• Research Site — Barcelona, Spain
• Research Site — Madrid, Spain

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.